Buy Skyrizi (risankizumab)

What is Skyrizi (risankizumab) for?

Skyrizi (risankizumab) is an interleukin-23 antagonist indicated to treat adults with:^[1]

• Plaque psoriasis that is moderate to severe in patients who are candidates for systemic therapy or phototherapy.
• Active psoriatic arthritis

It is available prefilled syringe and pen containing 150 mg/mL of risankizumab.^[1]

How does Skyrizi (risankizumab) work?

The active ingredient in Skyrizi, risankizumab, is a human monoclonal antibody, a type of protein, that binds to the cytokines interleukin (IL)-23. Cytokines play a role in signaling in a cell, especially in inflammation. Dysregulated production of and IL-23 were found to be very important in the development of specific diseases, such as psoriasis.^[2]

By binding to IL-23, tildrakizumab will block their action, and thereby slow down inflammation.^[1,2]

Where has Skyrizi (risankizumab) been approved?

Skyrizi (risankizumab) was approved by:

• The Food and Drug Administration (FDA), USA
  • On April 23, 2019 to treat moderate to severe plaque psoriasis.^[3]
  • On January 21, 2022 to treat active psoriatic arthritis.^[4]
• The European Medicines Agency (EMA)
  • On April 26, 2019 to treat moderate to severe plaque psoriasis.^[5]
  • On November 22, 2021 to treat active psoriatic arthritis.^[6]
• Therapeutic Goods Administration (TGA)
  • On July 23, 2019 to treat moderate to severe plaque psoriasis.^[7]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team. /contact-us

How is Skyrizi (risankizumab) taken?

The standard dosage is:^[1]

• The first two doses of 150 mg are given 4 weeks apart
• The following doses are given every 12 weeks

Skyrizi is administered as an injection beneath the skin (subcutaneous).^[1]

Skyrizi can be taken in a treatment center or at home after you receive training from your doctor.^[1]

Complete information about Skyrizi (risankizumab) dosage (modification) and administration can be found in the official prescribing information listed in our references section.^[1]

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Skyrizi (risankizumab)?

Common adverse reactions

The most common side effects (≥1% of patients) listed in the prescribing information include:^[1]

• Upper respiratory infections
• Headache
• Fatigue
• Injection site reactions
• Tinea infections

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:^[1]

• Hypersensitivity reaction
• Infections
• Tuberculosis (TB)

Use in a specific population

Skyrizi (risankizumab) may harm your unborn baby when administered to a pregnant woman. Skyrizi may affect fertility in females and males who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.^[1]

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.^[1]

References

1. Full prescribing information [FDA]: Skyrizi (risankizumab) [PDF] Novartis, Apr 2019

2. Targeting IL-23 in psoriasis: current perspectives
Fotiadou C, Psoriasis (Auckl.), Jan 4, 2018

3. AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
FDA press release, Apr 2019

4. U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis
FDA press release, Jan 2022

5. European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
EMA press release, Apr 2019

6. AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis
EMA press release, Nov 2021

7. AbbVie welcomes Therapeutic Goods Administration (TGA) – Regulatory Approval of SKYRIZI™ (risankizumab) [PDF] TGA press release, Jul 2019